This story was first published in digitalhealth.net
NICE asks Roche to submit a CDF proposal for urothelial cancer drug
NICE has invited Roche to submit a Cancer Drugs Fund (CDF) proposal for an immunotherapy treatment called atezolizumab.
The drug was assessed by NICE as a treatment for people who have advanced urothelial cancer.
It found that stronger evidence is needed to show the drug is both clinically and cost effective.
NICE is therefore asking Roche, a medicines and diagnosis development company, to submit a CDF proposal for atezolizumab. The drug is a form of immunotherapy which works by harnessing the power of the patient’s own immune system to destroy their cancer cells.
Including a drug in the CDF means patients can have access to it while the company gathers more data. This evidence may then be strong enough for the NICE committee to reconsider the drug and recommend it be available through the NHS.
Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “There is a lack of new treatment options for people who have advanced urothelial cancer, so I am very disappointed we’ve not been able to recommend atezolizumab at this stage.
“I hope Roche will work with us to submit a CDF proposal. Funding through the CDF means it could be offered to patients who cannot undergo chemotherapy while we collect more evidence. This will be a positive step for a lot of people.”
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
